Kornimate/medical-research-clean huggingface dataset:
ed90 of norepinephrine and phenylephrine infusions under intensive treatment

Conditions: Adverse Effect

Summary: the objective of this study is to investigate the ed90 of norepinephrine and phenylephrine infusions for preventing postspinal anesthesia hypotension under intensive treatment during cesarean section

post-spinal anesthesia hypotension is a frequent complication during spinal anesthesia for cesarean section. the incidence of post-spinal anesthesia hypotension is as high as 62.1-89.7% if prophylactic measures are not taken. the 2016 asa guidelines for obstetric anesthesia suggest avoiding hypotension following spinal anesthesia in women and emphasize the use of vasopressors, specifically alpha-receptor agonists, as the preferred strategy to prevent and manage post-spinal anesthesia hypotension. the 2018 international consensus in the united kingdom and northern ireland recommends maintaining maternal systolic blood pressure above 90% of the baseline value following lumbar anesthesia, while avoiding dropping below 80% of the baseline value. currently, the threshold for maintaining blood pressure above 80% of the baseline value is widely adopted as a standard; however, limited evidence supports the advantage of sustaining maternal blood pressure above 90% of the baseline value. the objective of this study is to investigate the ed90 of norepinephrine and phenylephrine infusions for preventing postspinal anesthesia hypotension under intensive treatment during cesarean section

Eligibility criteria:
inclusion criteria: * 18-45 years * primipara or multipara * singleton pregnancy ≥37 weeks * american society of anesthesiologists physical status classification i to ii * scheduled for cesarean section under spinal anesthesia exclusion criteria: * body height \< 150 cm * body weight \> 100 kg or body mass index (bmi) ≥ 40 kg/m2 * eclampsia or chronic hypertension or baseline blood pressure ≥180 mmhg * hemoglobin \< 7g/dl * fetal distress, or known fetal developmental anomaly
expanding access to care through telemedical support for vital sign monitoring in high-risk patients with cancer

Conditions: Hypertension

Summary: a randomized trial of remote blood pressure monitoring, compared to usual care, in patients receiving bevacizumab to determine whether remote blood pressure monitoring improves the collection of blood pressure data, identification and management of clinically significant hypertension, and patient satisfaction.

remote patient monitoring (rpm) technology has the potential to improve the early detection and management of clinically significant hypertension in cancer patients undergoing therapy with bevacizumab, by allowing immediate communication of abnormal measurements to the clinical care team. additionally, rpm may decrease patients' and caregivers' burdens of ongoing cancer care through an improved user experience compared to usual care.

Eligibility criteria:
inclusion criteria: 1. participant is a male or female 18 years of age or older. 2. participant is a current patient at west michigan cancer center/bronson cancer center. 3. participant is receiving bevacizumab as part of active treatment. 4. participant is willing and able to provide written informed consent. exclusion criteria: 1. participant is unable to understand english. 2. participant is hospitalized. 3. participants are unable to obtain blood pressure readings at home.
prevalence and effect of workplace stress among pediatric dentists

Conditions: Workplace Stress

Summary: work-related stress is a pattern of physiological, emotional, cognitive and behavioural reactions to some extremely taxing aspects of work content, work organization and work environment. certain work situations are too intense and frequent in nature that exceed an individual's coping capabilities and resources to handle them adequately dentistry is commonly known as a stressful profession among various occupations. frequent dealing with different types of patients, working in a very small area for long period of time , exposure to toxic substances , all these factors put the dentist under stress. adding to the previous factors, working to uncooperative children with annoying parents, will put pediatric dentistry on the top of the most stressful branches in dentistry. stress can affect pedodontists physiologically by increasing their blood pressure, heart rate, breathing rate and excessive sweating which in turn may increase the risk of hypertension and breathing problems.

all paricipants were informed about the objectives of the study and signed an informed consent before participating in the study. on the day of work, blood pressure and heart rate will be measured for every pediatric dentist at the beginning of the day before starting any case and will be measured again after 3 hours from continuous work. then, the two readings will be recorded and compared. this part will help in the physiological assessment of the study. the psychological part will be assessed by asking the pediatric dentists to answer the questions of the 2 scales. {appendices (2 \&3)} there will be a specially designed chart for fulfilling the aim of the study designed by the main investigator, this recording chart is formulated to collect the data from the participants. the recording chart is composed of 3 sections: the first section includes sociodemographic data the second section includes psychological assessment in which the score gets by each participant is recorded. the third section includes physiological assessment in which the first and second readings of heart rate and blood pressure are recorded and inspected for any change.

Eligibility criteria:
inclusion criteria: * both genders are included * postgraduate dentists submitting for master and phd in pediatric dentistry * medically free * the participants who sign the informed consent exclusion criteria: * participants taking drugs affecting nervous system * fasting participants
immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine in healthy volunteers aged 2 years and above

Conditions: Pneumonia, Pneumococcal

Summary: the purpose of this study is to evaluate immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine in healthy volunteers aged 2 years and above.


Eligibility criteria:
inclusion criteria: * 2 years old and above healthy people. * subject or legal representative who consent and has signed written informed consent. * subject or legal representative who is able to comply with all study procedures. * subject who didn't vaccinate pneumococcal vaccines and did't immune with any live vaccine within 14 days and inactivated vaccine within 7 days before vaccination. * axillary temperature ≤37.0 ℃. exclusion criteria: * history of allergy，eclampsia, epilepsy, encephalopathy and mental disease or family disease. * allergic history after vaccination. * known allergy to any component of the test vaccine（the test vaccine mainly contains 23 types of pneumococcal polysaccharide and pbs buffer） * subjects who diagnosis of thrombocytopenia or other history of coagulopathy. * known immunological impairment or dysfunction. * subjects who have received whole blood, plasma, and immunoglobulin therapy within one month. * known severe congenital malformations, developmental disorders; clinically diagnosed serious chronic diseases: down's syndrome, diabetes, sickle cell anemia or neurological disorders, guillain barre syndrome. * known or suspected to suffer from: respiratory system disease，acute infection or chronic disease active period，severe cardiovascular disease, liver and kidney disease, malignant tumor, skin disease,children's mother has hiv infection and other serious and infectious diseases. * in pregnancy or lactation or pregnant women. * subjects aged 18 years and above whose systolic blood pressure≥160mmhg and diastolic blood pressure≥100mmhg. * any contraindications that investigators consider related to vaccination.
vaccination against covid-19 in pregnant and lactating women in belgium

Conditions: Covid19

Summary: this study will investigate whether pregnant and lactating women can develop similar protective immunity as non-pregnant women against coronavirus infectious disease 2019 (covid-19) upon vaccination, without safety issues. immunogenicity and safety of all currently licensed covid-19 vaccines that are administered to pregnant and lactating women in belgium will be studied.

this project will compare vaccination of pregnant women with age-matched non-pregnant women and women vaccinated in the postpartum period during lactation. the primary objectives are to assess the immune responses (humoral immunity, cellular immunity, mucosal immunity) and safety after either administration of the comirnaty covid-19 vaccine (mrna, pfizer biontech), the covid-19 moderna vaccine (mrna, moderna), the covid-19 vaccine vaxzevria (viral vector, astra zeneca) or any other vaccine that will become available for the belgian population.

Eligibility criteria:
inclusion criteria: * female population older than 18 years. * ability to provide informed consent. * willing to be vaccinated with a covid-19 vaccine. * intend to be available for follow-up visits through one year postvaccination. * influenza and pertussis vaccination during pregnancy (as per belgian recommendations) is allowed. exclusion criteria: * serious underlying immunological condition (e.g. immunosuppressive disease or therapy, human immunodeficiency virus (hiv) infection...). * systemic treatment with immune suppressive medication, including chronic steroid use of \> 10 mg prednisone or equivalent. * anything in the opinion of the investigator that would prevent volunteers from completing the study or put the volunteer at risk.

Keywords: covid19 sars-cov-2 vaccination pregnancy lactating women breast milk humoral immune response cellular immune response maternal antibodies transplacental transmission
effect of robotised gait training on dynamic balance, symmetry and push-off in persons after stroke

Conditions: Stroke

Summary: rehabilitation robotics is increasingly used because it enables the patients to practice a wide array of movements. dynamic balance training is essential for gait rehabilitation and robotised devices enhance repeatability, objectivity and precision of such training combined with monitoring and recording of kinematic and kinetic data. the aim of the study is to explore the effect of robot-assisted gait training on dynamic balance, symmetry and take-off in patients after stroke. the investigators will conduct a randomised intervention study where one group will receive visual feedback on gait status and the other group will receive kinetically-assisted training using a robotised device in addition to the visual feedback.

gait training will start 3 weeks after admission to inpatient rehabilitation. it will last for 3 weeks, 5 times per week, 30 minutes per day. the first few sessions with the robotic device will serve to familiarise the patient with the bart device and training conditions. further details are described in the arms and interventions section.

Eligibility criteria:
inclusion criteria: * subacute phase after first ischaemic or haemorrhagic stroke (less than 6 months after stroke); * limb hemiparesis; * ability to walk independently (fac 6) or with assistance (fac 5) on flat and uneven surfaces, stairs and slopes; * adequate cardiovascular ability (nyha 1). exclusion criteria: * degenerative process or postoperative condition on lower-limb joints that would hinder gait; * associated neurological disease; * decreased cognitive ability (kpss \< 25).

Keywords: gait training dynamic balance gait symmetry rehabilitation robotics
utilization of amniotic membrane extract eye drop (ameed) on human corneal healing

Conditions: Cornea Injury

Summary: for severe ocular surface diseases, such as chemical and thermal injuries, stevens-johnson syndrome (sjs), band keratopathy, corneal dystrophies, refractive (prk-lasek), corneal surgery and others, it is important that short time treatment with minimal side effect should be considered. this study is a prospective clinical trial to use amniotic membrane extract eye drop (ameed) as a natural substance for acceleration of corneal healing

the cornea is the specific anterior part of eye that is essential for normal vision. the corneal surface is comprised of a unique type of non-keratinized epithelial cell. corneal epithelium contains transient amplifying cells and post mitotic cells. the limbal stem cells (lsc) are located between limbal cornea and conjunctiva which are main source of corneal epithelium healing in eye injuries. for some corneal disease such as chemical and thermal injuries, corneal dystrophies and corneal surgery, treatment in short time is important. am can modulate corneal epithelium healing by promoting re-epithelialization and migration of limbal stem cell while suppressing stromal inflammation, angiogenesis and scarring. this biological substrate maintain epithelial progenitor cells within the limbal stem cell niche and facilitate ocular surface epithelial renewal. it is well accepted that amniotic membrane transplantation (amt) as a temporary patch normally dissolves within 2 weeks. consequent reapplication of membrane is difficult for the patient. other studies have been reported that processed am as a liquid has comparable effect to amt in treatment of corneal epithelial healing. this study is a prospective clinical trial to use amniotic membrane extract eye drop (ameed) as a natural substance for acceleration of corneal healing.

Eligibility criteria:
inclusion criteria: 1. patient with corneal epithelium injury 2. without keratoconus 3. without cornea scar 4. without any other lesion of cornea exclusion criteria: 1. lack of timely referral of patients for examinations 2. simultaneous use of other drugs that cause impairment of the data 3. previous cornea surgery 4. dry eye 5. glaucoma

Keywords: cornea epithelium healing amniotic membrane eye drop
high frequency oscillatory ventilation versus high frequency jet ventilation for congenital diaphragmatic hernia

Conditions: Congenital Diaphragmatic Hernia

Summary: the purpose of this study is to conduct a prospective study of all congenital diaphragmatic hernia (cdh) neonates managed at the university of utah newborn intensive care unit (nicu) and primary children's hospital nicu that required mechanical ventilation at birth. as both high frequency jet ventilation (hfjv) and high frequency oscillatory ventilation (hfov) are standard approaches to ventilatory support of all neonates including cdh, cdh infants will be randomized at the time of birth or admission to either hfjv or hfov as initial ventilator mode, stratified by position of the liver in the abdomen or thorax (if known) by 24 hours of age. measures of oxygenation, ventilation and hemodynamics of the cdh cohort managed on hfov compared to those on hfjv.


Eligibility criteria:
inclusion criteria: 1. admitted to either the university of utah and/or primary children's hospital nicu within 24 hours of birth 2. requiring mechanical ventilation 3. umbilical arterial line or peripheral arterial line in place 4. obtained signed consent 5. infant is ≤ 24 hours of age exclusion criteria: 1. severe anomaly 1. chromosomal abnormalities 2. major congenital anomalies, including cardiac, central nervous system and syndromes 2. post-natal diagnosis \> 24 hours of life 3. unable to obtain consent for participation 4. unable to randomize within 24 hours of life
evaluating impact and implementation of choose to move (phase 3)

Conditions: Aging; Physical Inactivity; Mobility Limitation; Loneliness; Social Isolation

Summary: the objectives of this study are to 1) evaluate whether choose to move (ctm) improves health outcomes in older adults who participate and 2) assess whether ctm is delivered as planned and what factors support or inhibit delivery at scale. ctm is a 6 month, choice-based program for low active older adults being scaled-up across british columbia, canada. the goals of ctm are to enhance physical activity, mobility and social connectedness in older adults living in british columbia, canada.

ctm is a 6 month, choice-based program for low active older adults being scaled-up in phases across british columbia, canada. within ctm (phase 3), trained activity coaches support older adults in three ways. first, in a one-on-one consultation, activity coaches help participants to set goals and create action plans for physical activity tailored to each person's interests and abilities. older adults can choose to participate in individual or group-based activities. second, activity coaches facilitate a series of group meetings with small groups of participants. finally, activity coaches regularly check in with participants to provide ongoing support. activity coaches and recreation departments across bc are trained and provided with resources to deliver ctm. objectives: 1. to assess the impact (effectiveness) of ctm (phase 3) delivered at scale on the physical activity, mobility and social connectedness of older adults (part i - impact evaluation) 2. to assess whether the program was implemented as planned (fidelity) and investigate factors that support or inhibit implementation at scale (part ii - implementation evaluation). study design: we use a hybrid type 2 effectiveness-implementation (curran et al 2012) pre-post study design to evaluate ctm. we use mixed-methods (quantitative and qualitative) and collect data at 0 (baseline), 3 (mid-intervention), 6 (post-intervention) and 18 (12-months post-intervention) months to assess effectiveness and implementation of ctm.

Eligibility criteria:
inclusion criteria (older adults): * ≥60 years of age, * demonstrate readiness for physical activity via the par-q+ questionnaire (warburton et al 2011), get active questionnaire (canadian society for exercise physiology 2017) or a letter of recommendation from their physician * \<150 min/week physical activity * english speaking exclusion criteria (older adults): - previous participation in ctm inclusion criteria (delivery partners): * activity coaches will be english speaking bcrpa registered older adult fitness leaders or kinesiologists who are delivering ctm at participating centres * recreation managers and coordinators affiliated with participating centres delivering ctm * provincial partners (e.g., individuals/partners who make strategic and/or policy decisions) at partner organizations delivering choose to move

Keywords: implementation science scale-up behaviour change physical activity mobility loneliness social connectedness social isolation older adults fidelity adaptation
placenta perfusion and sufficiency study

Conditions: Placenta Diseases, Diagnosis; Pregnancy Related; Female; Human

Summary: ultrasonography will be used to determine the total blood flow to and from the uterus. this is done by measuring the blood vessels coming from and going to the uterus. this wil hopefully prove viable and open the possibility to further research in the clinical relevance of these measurements.

this prospective pilot study takes place between 14- and 16-weeks' gestation (ga14 to 16 weeks). this is a feasibility study, as the perfusion measurements have not yet been performed this early in pregnancy. first the feasibility is assessed, before conducting a full-scale research project. the study will take place in a tertiary care obstetric centre, máxima medical center, in veldhoven the netherlands. measurements will be done at the out patient clinic of obstetrics. duration of the study is 2 months. this gives ample time for recruitment of the subjects. recruitment will take place at the outpatient clinic of máxima medisch centrum in veldhoven. women with singleton pregnancies coming for their 11-12 weeks' gestational ultrasound, where the pregnancy is dated, will be given a patient information folder in either dutch or english and asked if the researcher can contact them. participation is completely on voluntary basis. patients will be called in the next days by the researcher to answer additional questions and to ask if patients are willing to participate. contact information of the researchers will be available on the folder in case of questions. upon inclusion, the patients will be scheduled for a visit to perform all relevant measurements, henceforth referred to as 'measurement day' (md) which is to take place between 14- and 16-weeks' gestation. the patient, henceforth to be referred to as participant, will be asked to rest for 5 minutes in a supine position. after 5 minutes of rest the blood pressure of the right arm will be measured, three times using the auto-sphygmomanometer. the three measurements will then be used to calculate the average systolic and diastolic blood pressures. after measurement of blood pressure, the ultrasound scan will be performed. the uterine and placental vessels will be measured according to the standard operating procedure attached to this document. all vessels will be measured 3 times during the ultrasound scan.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * between 14-16 weeks gestation on measurement day * placenta anterior * bmi \< 30kg/m2 * ability to give consent * adequate mastery of the dutch or english languages exclusion criteria: * non-intact pregnancy at 13 week's gestational echo. * vanishing twin * multiple gestations * congenital or anatomical anomalies at 13 weeks' gestational echo.

Keywords: placenta human pregnancy early pregnancy hypertension disorders uterus uterine artery uterine vein placental circulation placenta physiology netherlands placenta development
study of som0226 in familial amyloid polyneuropathy

Conditions: Familial Amyloid Polyneuropathy (FAP)

Summary: clinical proof of concept study to evaluate som0226 efficacy in ttr amyloidosis.

this is an open label interventional phase iia proof of concept clinical trial designed in two phases separated by a washout period of 6 weeks (± 2 weeks) , to evaluate the ttr stabilization activity of som0226 in healthy volunteers (wild type), ttr-fap patients and asymptomatic carriers. * phase a (24 hours): som0226 single dose * phase b (32 hours): som0226 multiple dose

Eligibility criteria:
inclusion criteria: * participant is willing and able to give informed consent for participation in the study * male or female, aged 18 years or above at the time of consent * two cohorts defined by ttr variant (wild type: healthy volunteers; ttr mutant: asymptomatic carriers with documented mutation in ttr or diagnosed ttr-fap patients (stage 1 or 2) not undergoing pharmacological treatment with vyndaqel * body mass index (bmi) \> 17.5 kg/m2 * female participants of child bearing potential and male participants whose partner is of child bearing potential must be willing to ensure that they or their partner use effective contraception during the study and for 2 month thereafter * able (in the investigators opinion) and willing to comply with all study requirements exclusion criteria: * female participant who is pregnant, lactating or planning pregnancy during the course of the study * evidence of history of clinically significant hepatic disease * an alt or ast measurement \> 2 times the uln (upper limit of normal) * scheduled elective surgery or other procedures requiring general anaesthesia during the study * donation of blood during the study or within the past 4 weeks * treatment (during the study or within the past 4 weeks) with a prescription or investigational drug for the treatment of ttr amyloidosis * treatment with nsaids (nonsteroidal antiinflammatory drug) during the study or within the past 4 weeks. the following nsaid are allowed: acetylsalicylic acid, etodolac, ibuprofen, indomethacin, ketoprofen, nabumetone, naproxen, nimesulide, piroxicam and sulindac

Keywords: transthyretin ttr amyloidosis som0226 familiar amyloid polyneuropathy